Skip to main content
main-content

Bone diseases

Highlights

03-06-2019 | Rheumatoid arthritis | Highlight | News

IL-6 receptor inhibition may induce bone erosion repair in RA

Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.

24-05-2019 | Rheumatoid arthritis | Highlight | News

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

24-04-2019 | Osteoporosis | Highlight | News

Long-term drug treatment may reduce fracture risk in women with osteoporosis

Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.

01-03-2019 | Osteoarthritis | Highlight | Article

Early-onset osteoarthritis in association with familial angel-shaped phalango-epiphyseal dysplasia previously referred to as peripheral dysostosis

Editorial board member Oliver FitzGerald presents a family with two siblings having features consistent with angel-shaped phalango-epiphyseal dysplasia (ASPED), and a mother with a normal phenotype but with severe, early-onset multi-joint osteoarthritis.

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

27-10-2018 | Denosumab | ACR/ARHP 2018 | Video

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

02-10-2018 | Osteopenia | Highlight | News

Zoledronate benefits postmenopausal women with osteopenia

Treatment with zoledronate once every 18 months significantly reduces the risk for nonvertebral or vertebral fragility fractures, compared with placebo, in postmenopausal women with osteopenia, study findings indicate.

29-08-2018 | Osteoporosis | Review | Article

Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis

Hussain S et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4142-x

27-07-2018 | Bone diseases | Case report | Article

Unusual case of chronic recurrent multifocal osteomyelitis

The authors present a rare case of sporadic chronic recurrent multifocal osteomyelitis in which the patient eventually developed cytoplasmic anti-neutrophil cytoplasmic antibodies-associated renal vasculitis and hyperparathyroidism.

Snipaitiene A et al. Pediatr Rheumatol 2018; 16: 49. doi: 10.1186/s12969-018-0267-4

18-07-2018 | Osteoporosis | Article

Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis

Liu J et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4630-6

21-06-2018 | Osteoporosis | Review | Article

Physical activity for fall and fracture prevention

The aim of this review is to provide healthcare professionals with evidence-based physical activity recommendations, and tips for implementing them in practice.

Ponzano M, Rodrigues IB, Giangregorio LM. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0103-5

31-05-2018 | Osteoporosis | View from the clinic | Article

Monitoring bone health with dual-energy X-ray absorptiometry in pediatric patients

Advisory board member and consultant endocrinologist Malachi McKenna summarizes the use of dual-energy X-ray absorptiometry in monitoring bone health and diagnosing low bone mineral mass in children.

31-05-2018 | Osteoporosis | View from the clinic | Article

Managing osteoporosis in pediatric patients

Editorial board member Sangeeta Sule discusses the causes of low bone mineral density and osteoporosis in pediatric patients with rheumatic diseases, and suggests strategies for risk prevention and treatment of this disease.

08-05-2018 | Osteoarthritis | Article

Benefits and safety of dietary protein for bone health: An expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation

This summary of systematic reviews and meta-analyses addresses the benefits and risks of dietary protein intakes for bone health in adults.

Rizzoli R et al. Osteoporos Int 2018; Advance online publication. doi: 10.1007/s00198-018-4534-5

12-04-2018 | Osteoporosis | Article | News

Trial results back denosumab as a treatment option for glucocorticoid-induced osteoporosis

Patients with glucocorticoid-induced osteoporosis who are treated with denosumab have greater improvements in bone mineral density than those treated with risedronate, phase III trial results suggest.

23-02-2018 | Osteoporosis | Case report | Article

Multiple vertebral fractures associated with glucocorticoid-induced osteoporosis treated with teriparatide followed by kyphosis correction fusion: A case report

The authors report the case of a 24-year-old woman diagnosed with glucocorticoid-induced osteoporosis in which initial treatment with teriparatide followed by treatment of kyphosis with correction fusion achieved a favorable outcome.

Uei H et al. Osteoporos Int 2018; Advance online publication. doi: 10.1007/s00198-018-4425-9

21-03-2017 | Osteoporosis | Case report | Article

Case report: Fast reversal of severe osteoporosis after correction of excessive levothyroxine treatment and long-term follow-up

This case report describes a 38-year-old woman, who presented with bilateral femoral stress fractures and osteoporosis after years of excessive levothyroxine treatment. How would you respond when presented with such a patient?

Laine CM, K. Landin-Wilhelmsen K. Osteoporos Int 2017; 28: 2247–2250. doi:10.1007/s00198-017-3981-8

Image Credits